Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sinopharm Tech Holdings Limited
國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)

GRANT OF SHARE OPTIONS

The Board announces that on 7 January 2020, the Company granted an aggregate of 92,800,000 Options, subject to acceptance of the Grantees, to subscribe for the Shares under the Scheme and of which 26,000,000 Options were granted to the Directors, chief executive and their associates.

This announcement is made pursuant to Rule 23.06A of the Rules (the "**GEM Listing Rules**") Governing the Listing of Securities on GEM ("**GEM**") of the Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The board (the "**Board**") of directors (the "**Director(s)**") of Sinopharm Tech Holdings Limited (the "**Company**") hereby announces that on 7 January 2020, the Company granted share options (the "**Option(s)**") to certain eligible persons, being the Directors, chief executive and certain employees of the Company and its subsidiaries (the "**Grantee(s)**") pursuant to the share option scheme of the Company adopted on 31 January 2013 (the "**Scheme**") to subscribe for 92,800,000 ordinary shares of HK$0.0125 each in the share capital of the Company (the "**Share(s)**"), subject to acceptance of the Grantees. Details of such grant are as follows:

Date of Grant:	7 January 2020
Exercise price of the Options granted:	HK$0.33 per Share
Closing price of the Shares on the date of grant of the Options:	HK$0.244 per Share
Number of Options granted:	92,800,000 Options, each Option shall entitle the Grantees to subscribe for one Share

Validity period of the Options granted:	From the date of grant up to 31 December 2022 (both days inclusive) and the Options granted are exercisable in stages from 1 June 2020 up to 31 December 2022 (both days inclusive), subject to the provisions for each termination contained in the Scheme and certain vesting conditions applicable to the relevant Grantee(s)

Among the total of 92,800,000 Options granted, 26,000,000 Options were granted to the following Directors, chief executive and their associates:

Name	**Position**	**No. of Options granted**
Madam CHEUNG Kwai Lan	Chairperson, Executive Director	4,000,000
Mr. CHAN Ting	Deputy Chairman, Chief Executive Officer and Executive Director	4,000,000
Mr. CHAN Tung Mei	Non-executive Director	3,600,000
Dr. CHENG Yanjie	Non-executive Director	3,600,000
Dr. LIU Ta-pei	Independent Non-executive Director	3,600,000
Mr. CHAU Wai Wah Fred	Independent Non-executive Director	3,600,000
		22,400,000
Ms. CHAN Siu Sarah	General Counsel (Directors' associates)	3,600,000
Total		**26,000,000**

The grant of the Options to the above Directors, chief executive and their associates has been approved by the independent non-executive Directors of the Company (excluding independent non-executive Directors who are the Grantees). Save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or their respective associates (as defined in the GEM Listing Rules).

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Executive Director and Chief Executive Officer

Hong Kong, 7 January 2020

As at the date of this announcement, the Board comprises Madam CHEUNG Kwai Lan and Mr. CHAN Ting as executive Directors, Mr. CHAN Tung Mei and Dr. CHENG Yanjie as non-executive Directors and Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.